{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=keyhole+limpet+hemocyanin&page=2",
    "query": {
      "intervention": "keyhole limpet hemocyanin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 42,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=keyhole+limpet+hemocyanin&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=keyhole+limpet+hemocyanin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T15:39:45.477Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01489956",
      "title": "A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Autoimmune Disorders"
      ],
      "interventions": [
        {
          "name": "Immucothel Alone (Part A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immucothel+Montanide (Part A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immucothel Alone or Immucothel+Montanide (Part B)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 19,
      "start_date": "2011-12",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-12",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489956"
    },
    {
      "nct_id": "NCT02754362",
      "title": "A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly-ICLC as immune adjuvant",
          "type": "DRUG"
        },
        {
          "name": "Keyhole limpet hemocyanin (KLH)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-11",
      "completion_date": "2019-06",
      "has_results": false,
      "last_update_posted_date": "2020-01-13",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02754362"
    },
    {
      "nct_id": "NCT00000105",
      "title": "Vaccination With Tetanus and KLH to Assess Immune Responses.",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Intracel KLH Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biosyn KLH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide ISA51",
          "type": "DRUG"
        },
        {
          "name": "Tetanus toxoid",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2002-07",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000105"
    },
    {
      "nct_id": "NCT01027780",
      "title": "Mindfulness to Improve Elders' Immune and Health Status",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress, Psychologic"
      ],
      "interventions": [
        {
          "name": "Mindfulness-Based Stress Reduction",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2006-03",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2014-08-27",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027780"
    },
    {
      "nct_id": "NCT05163080",
      "title": "SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Newly Diagnosed Glioblastoma"
      ],
      "interventions": [
        {
          "name": "SurVaxM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MimiVax, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 247,
      "start_date": "2021-11-18",
      "completion_date": "2024-08-18",
      "has_results": false,
      "last_update_posted_date": "2024-02-26",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Miami, Florida • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Summit",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05163080"
    },
    {
      "nct_id": "NCT02079480",
      "title": "Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Volunteers"
      ],
      "interventions": [
        {
          "name": "BMS-986090",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with BMS-986090",
          "type": "DRUG"
        },
        {
          "name": "Keyhole limpet hemocyanin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 130,
      "start_date": "2014-05",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2016-05-12",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02079480"
    },
    {
      "nct_id": "NCT00470574",
      "title": "Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "QS21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 7,
      "start_date": "2007-03-20",
      "completion_date": "2020-01-24",
      "has_results": true,
      "last_update_posted_date": "2020-11-18",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470574"
    },
    {
      "nct_id": "NCT00017290",
      "title": "Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "keyhole limpet hemocyanin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genitope Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 21,
      "location_summary": "Dublin, California • Greenbrae, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00017290"
    },
    {
      "nct_id": "NCT00004929",
      "title": "Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "MUC-2-KLH vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS21",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "1999-09",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004929"
    },
    {
      "nct_id": "NCT00019097",
      "title": "Vaccine Therapy in Treating Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma",
        "Refractory Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "autologous tumor cell vaccine",
          "type": "DRUG"
        },
        {
          "name": "keyhole limpet hemocyanin",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1995-07",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-10-06T15:39:45.477Z",
      "location_count": 3,
      "location_summary": "Little Rock, Arkansas • Bethesda, Maryland",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019097"
    }
  ]
}